<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: To analyze in a random urine spot the predictive value of urinary albumin concentration (UAC) for cardiovascular events, diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> (DN), and <z:hpo ids='HP_0011420'>death</z:hpo> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: In this cohort, urinary albumin (immunoturbidimetry) was measured as 24-h urinary albumin excretion (UAE) and, in a random spot urine, as UAC and albumin:<z:chebi fb="0" ids="16737">creatinine</z:chebi> ratio (ACR) </plain></SENT>
<SENT sid="2" pm="."><plain>Primary outcomes were: 1) cardiovascular events, 2) DN defined as a composite outcome [macroalbuminuria and/or decreased glomerular filtration rate (GFR) &lt;60ml/min/1.73m(2)], and 3) <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: A total of 199 type 2 diabetic patients, aged 59.9±9.9years, were followed for 6.1±2.7years </plain></SENT>
<SENT sid="4" pm="."><plain>UAC ≥14.4mg/l, as determined by ROC curve, predicted DN and prediction for this and other outcomes were compared with traditional <z:mp ids='MP_0002959'>microalbuminuria</z:mp> cutoffs for ACR and UAE </plain></SENT>
<SENT sid="5" pm="."><plain>The outcomes frequency was: cardiovascular events=26.4%, DN=31.7% (23.5% <z:mp ids='MP_0005528'>decreased GFR</z:mp>; 13.6% macroalbuminuria) and <z:hpo ids='HP_0011420'>death</z:hpo>=8.50% </plain></SENT>
<SENT sid="6" pm="."><plain>In Cox analyses, UAC ≥14mg/l increased the risk (hazard ratio, HR) for cardiovascular events 3.25 times (95% CI 1.43-7.38; P=0.005), 4.30 for DN composite outcome (95% CI 2.22-8.32; P&lt;0.001), and 5.51 for <z:hpo ids='HP_0011420'>death</z:hpo> (95% CI 1.16-26.22; P=0.032) </plain></SENT>
<SENT sid="7" pm="."><plain>Corresponding HRs of ACR ≥30mg/g were: 2.89 (95% CI 1.29-6.45; P=0.009) for cardiovascular events, 4.67 (95% CI 2.34-9.34; P&lt;0.001) for DN composite outcome and 5.07 (95% CI 1.01-24.88; P=0.049) for <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>HRs of UAE ≥30mg/24-h were: 2.20 (95% CI 2.08-2.49; P=0.030) for cardiovascular events, 6.76 (95% CI 3.32-13.77; P&lt;0.001) for DN composite outcome, and 2.47 (95% CI 0.72-8.42; P=0.150) for <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In conclusion, random UAC ��14mg/l predicted cardiovascular events, diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, and mortality just as well as ACR </plain></SENT>
<SENT sid="10" pm="."><plain>UAC may be used to assess cardiovascular and renal risks in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>